STAT3 as a target of molecular targeting therapy for oral cancer: Cell-based screening using inhibitor screening kits

Asian Journal of Oral and Maxillofacial Surgery

Volumn 23, Issue 4, 2011, Pages 167-171

  Nagumo, Tatsuhito ^a   Ito, Daisuke ^b   Tsukamoto, Hikari ^a   Yasuda, Arisa ^a   Shintani, Satoru ^a  

^a SHOWA UNIVERSITY   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Apoptosis; Molecular targeting; Oral cancer; STAT3; Survivin

Indexed keywords

EID: 80054109354     PISSN: 09156992     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajoms.2011.06.007     Document Type: Article

References (21)

1. Kawada M., Inoue H., Masuda T., Ikeda D. Insulin-like growth factor-I secreted from prostate stromal cells mediates tumor-stromal cell interactions of the prostate cancer. Cancer Res 2006, 66:4415-4419.
2. Tsuchiya A., Tashiro E., Yoshida M., Imoto M. Involvement of protein phosphatase 2A nuclear accumulation and subsequent inactivation of activator protein-1 in leptomycin B-inhibited cyclin D1 expression. Oncogene 2007, 26:1522-1532.
3. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 2002, 3:651-662.
4. Hamakawa H., Nakashiro K., Sumida T., Shintani S., Myers J.N., Takes R.P., et al. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer. Head Neck 2008, 30:800-809.
5. Bonner J.A., Harari P.M., Giralt J., Azarnia N., Shin D.M., Cohen R.B., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
6. Macha M.A., Matta A., Chauhan S., Siu K.M., Ralhan R. 14-3-3 zeta is a molecular target in guggulsterone induced apoptosis in head and neck cancer cells. BMC Cancer 2010, 10:655.
7. Yamada S., Yanamoto S., Kawasaki G., Rokutanda S., Yonezawa H., Kawakita A., et al. Overexpression of CRKII increases migration and invasive potential in oral squamous cell carcinoma. Cancer Lett. 2011, 28(2):84-91.
8. Darnell J.E. Transcription factors as targets for cancer therapy. Nat Rev Cancer 2002, 2:740-749.
9. Yu H., Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004, 4:97-105.
10. Bowman T., Yu H., Sebti S., Dalton W., Jove R. Signal transducers and activators of transcription: novel targets for anticancer therapeutics. Cancer Control 1999, 6:427-435.
11. Turkson J., Jove R. STAT proteins: novel molecular targets for cancer drug discovery. Oncogene 2000, 19:6613-6626.
12. Bowman T., Garcia R., Turkson J., Jove R. STATs in oncogenesis. Oncogene 2000, 19:2474-2488.
13. Niu G., Heller R., Catlett-Falcone R., Coppola D., Jaroszeski M., Dalton W., et al. Gene therapy with dominant-negative STAT3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res 1999, 59:5059-5063.
14. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., et al. Constitutive activation of STAT3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
15. Blaskovich M.A., Sun J., Cantor A., Turkson J., Jove R., Sebti S.M. Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. Cancer Res 2003, 63:1270-1279.
16. Jing N., Tweardy D.J. Targeting Stat3 in cancer therapy. Anticancer Drugs 2005, 16:601-607.
17. Aoki Y., Feldman G.M., Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 2003, 101:1535-1542.
18. Kanda N., Seno H., Konda Y., Marusawa H., Kanai M., Nakajima T., et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004, 23:4921-4929.
19. Li F. Survivin study: what is the next wave?. J Cell Physiol 2003, 197:8-29.
20. Lo Muzio L., Pannone G., Staibano S., Mignogna M.D., Rubini C., Mariggio M.A., et al. Survivin expression in oral squamous cell carcinoma. Br J Cancer 2003, 89:2244-2248.
21. Scheper M.A., Nikitakis N.G., Sauk J.J. Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer. Int J Oral Maxillofac Surg 2007, 36:632-639.